Iceland· IS-EU/1/13/848/001
Erivedge
A vismodegib product containing vismodegibum inn, registered in Iceland by Roche Registration GmbH*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Vismodegib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XJ01 (vismodegib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Vismodegib · ATC L01XJ01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vismodegib costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Vismodegib · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$228.97
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Vismodegibum INN
- Manufacturer
- Roche Registration GmbH*
- Country
- Iceland (IS)
- ATC code
- L01XJ01
- ATC class
- Vismodegib
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
69 interactions on record for vismodegib.
Graded by severity as the source publishes them — 45 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vismodegib · interactions on record
69 records
- 45 moderate
- 24 minor
Most severe, free to view
- QuinidineC01BA01moderate
- PropafenoneC01BC03moderate
- AmiodaroneC01BD01moderate
- DronedaroneC01BD07moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vismodegib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayErivedgeRoche Registration GmbH
- FinlandErivedgeParanova Oy
- SwitzerlandErivedge
- CzechiaERIVEDGERoche Registration GmbH, Grenzach-Wyhlen
- SpainERIVEDGE 150 MG CAPSULAS DURASRoche Registration Gmbh
- FranceERIVEDGE 150 mg, géluleROCHE REGISTRATION (ALLEMAGNE)
- United KingdomErivedge 150mg capsulesRoche Products Ltd
- IrelandErivedge 150 mg hard capsulesRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Erivedge
- Norway · Erivedge
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/28979589-2ab0-4c2d-9eaa-b031ddec7eff GET /v1/drugs/28979589-2ab0-4c2d-9eaa-b031ddec7eff?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Hart hylki",
"source": "lyfjastofnun",
"atc_raw": "L01XJ01",
"marketed": false,
"strength": "150 mg",
"ma_number": "EU/1/13/848/001",
"substance": "Vismodegibum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í krabbameinslækningum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "41467"
}See everything about vismodegib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.